Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Landgren O, Hultcrantz M, Diamond B, Lesokhin AM, Mailankody S, Hassoun H, Tan C, Shah UA, Lu SX, Salcedo M, Werner K, Rispoli J, Caple J, Sams A, Verducci D, Jones K, Concepcion I, Ciardello A, Chansakul A, Schlossman J, Tavitian E, Shekarkhand T, Harrison A, Piacentini C, Rustad EH, Yellapantula V, Maclaughlan K, Maura F, Landau HJ, Scordo M, Chung DJ, Shah G, Lahoud OB, Thoren K, Murata K, Ramanathan L, Arcila ME, Ho C, Roshal M, Dogan A, Derkach A, Giralt SA, Korde N. Landgren O, et al. Among authors: tavitian e. JAMA Oncol. 2021 Jun 1;7(6):862-868. doi: 10.1001/jamaoncol.2021.0611. JAMA Oncol. 2021. PMID: 33856405 Free PMC article. Clinical Trial.
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition.
Pianko MJ, Devlin SM, Littmann ER, Chansakul A, Mastey D, Salcedo M, Fontana E, Ling L, Tavitian E, Slingerland JB, Slingerland AE, Clurman A, Gomes ALC, Taur Y, Pamer EG, Peled JU, van den Brink MRM, Landgren O, Lesokhin AM. Pianko MJ, et al. Among authors: tavitian e. Blood Adv. 2019 Jul 9;3(13):2040-2044. doi: 10.1182/bloodadvances.2019032276. Blood Adv. 2019. PMID: 31289031 Free PMC article.
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2 ) in combination with lenalidomide and dexamethasone.
Korde N, Mastey D, Tavitian E, Mailankody S, Lesokhin A, Hassoun H, Smith EL, Lendvai N, Hultcrantz M, Shah U, Tan C, Lu S, Diamond B, Salcedo M, Werner K, Chung DJ, Scordo M, Shah GL, Lahoud O, Landau H, Arcila M, Ho C, Roshal M, Dogan A, Derkach A, Devlin SM, Giralt SA, Landgren O. Korde N, et al. Among authors: tavitian e. Am J Hematol. 2021 Jun 1;96(6):E193-E196. doi: 10.1002/ajh.26150. Epub 2021 Mar 19. Am J Hematol. 2021. PMID: 33661527 Free PMC article. Clinical Trial. No abstract available.
Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study.
Mailankody S, Salcedo M, Tavitian E, Burge M, Korde N, Hassoun H, Lesokhin A, Lahoud O, Smith E, Hultcrantz M, Tan C, Shah U, Devlin S, Landgren O. Mailankody S, et al. Among authors: tavitian e. Leuk Lymphoma. 2022 Nov;63(11):2760-2761. doi: 10.1080/10428194.2022.2095626. Epub 2022 Jul 15. Leuk Lymphoma. 2022. PMID: 35838493 No abstract available.
Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study.
Korde N, Tavitian E, Mastey D, Lengfellner J, Hevroni G, Zarski A, Salcedo M, Mailankody S, Hassoun H, Smith EL, Hultcrantz M, Shah U, Tan C, Diamond B, Shah G, Scordo M, Lahoud O, Chung DJ, Landau H, Giralt S, Derkach A, Atkinson TM, Sabbatini P, König F, Usmani SZ, Landgren O, Lesokhin AM. Korde N, et al. Among authors: tavitian e. EClinicalMedicine. 2023 Feb 27;57:101854. doi: 10.1016/j.eclinm.2023.101854. eCollection 2023 Mar. EClinicalMedicine. 2023. PMID: 36895800 Free PMC article.
13 results